Navigation Links
BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters
Date:11/19/2008

BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. delivered the keynote presentation on Wednesday, November 19, at a meeting in Madison, Wisconsin commemorating the 10th anniversary of the publication describing the first derivation and culturing of human embryonic stem cells. Dr. West’s presentation is titled “Opportunities and Challenges of Commercializing Stem Cell Research.” The Wisconsin Academy, along with University of Wisconsin-Madison and the Wisconsin Alumni Research Foundation (WARF), hosted the two-day event titled “A Decade Celebrating Stem Cells: Changing the Face of Medicine Ten Years Later” to commemorate the publication of the first derivation of human embryonic stem cells and to examine future trends.

ALAMEDA, Calif. (Business Wire EON) November 19, 2008 -- Dr. West's presentation included a historical overview of the biotechnology industry, a description of historical trends in the industry of commercializing stem cell technology, and a discussion of future opportunities for the field. Dr. West discussed BioTime's stem cell research program that is focused on opportunities for near-term revenues in the development and marketing of products derived from stem cells.

  • West announced the launch of ten new cell line products and presented data on their unique properties and potential utility in regenerative medicine. The molecular markers of these lines are consistent with varied types of human neural crest, mesodermal, and CNS progenitor cells that have promise for the treatment of numerous diseases such as cranial-facial, muscular, and neurological disorders. Information about these cell lines will be available online at www.embryome.com starting Monday, November 24, 2008, and the cells themselves are now available for purchase for research purposes only through the same website.

Lastly, Dr. West discussed federal policies relating to the industry of regenerative medicine. He announced an open letter to President-Elect Obama signed by 22 scientists and economists (including 19 Nobel laureates), urging the new Administration to make regenerative medicine, specifically, the cure of human disease, a national priority, similar in scope to the Kennedy Administration's commitment to land a man on the moon within that decade. The text of the letter to President-Elect Obama is available online at www.biotimeinc.com.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.

BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Read the full story at http://www.prweb.com/releases/stem_cell/michael_west/prweb1645174.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative
2. Michael J. Fox Foundation Names Core Programs in Honor of Humanitarian Edmond J. Safra
3. Vocollect Healthcare Systems Names Michael French as Vice President of Customer Experience
4. UCSF Chancellor J. Michael Bishop Announces Plan To Step Down
5. Majesco Entertainment and Interactive Game Group Announce Jillian Michaels Fitness Ultimatum 2009 Ships to Stores October 21st
6. US Oncology Appoints Michael A. Sicuro Executive Vice President and Chief Financial Officer
7. Quorum Review IRB Appoints Michael Malafronte Director of Quality and Document Administration
8. Michael J. Fox Foundation Awards One Million Dollars for Development of Trojan Horse Delivery Technology to Treat Parkinsons Disease
9. Catholic Health East Acquires Saint Michaels Medical Center
10. Michael and Terry Ward Donate $1 Million to Wounded Warrior Project (WWP)
11. Rock The Cradles Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters 
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: